EUVIMEDEUVIMED entdecken
Crossref

[ 18 F]NP3‐627, a Candidate PET Imaging Agent Targeting the NLRP3 Inflammasome in the Central Nervous System

David M Whitehead, Christian Fischer iD, Emmanuelle Briard iD, Christopher J Farady iD, Nadège Graveleau, Joel Karrer, Klemens Kaupmann iD, Guillaume Lapointe iD, Angela Mackay iD, Lisa Reichert iD, Michael Wright, Linjing Mu iD und 1 weitere

ChemMedChem · 16.02.2025 · 20 (4)

DOI: 10.1002/cmdc.202400816 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ChemMedChem, online erschienen am 27.11.2024. Verfasst von David M Whitehead und 12 weiteren Autor:innen. Beteiligte Einrichtung: Novartis Biomedical Research, Global Discovery Chemistry, Novartis Campus, WSJ-88.10.110, 4056, Basel, Switzerland. Hauptthemen laut MEDLINE: Positron-Emission Tomography, NLR Family, Pyrin Domain-Containing 3 Protein, Pyridazines, Inflammasomes. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 36 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We describe the identification of a candidate positron emission tomography (PET) imaging agent for the NLRP3 protein. NLRP3 plays a critical role in the immune system and has proven a difficult target for the development of imaging agents due to its low and cell‐specific expression profile. A recently described series of pyridazine‐based inhibitors, with improved permeability and brain‐penetration properties, was used as a starting point for the development of a suitable PET imaging agent. Optimization of affinity, non‐specific binding and pharmacokinetic properties led to the identification of aminopyridazine ( R )‐2‐(6‐((1‐cyclopropylpiperidin‐3‐yl)amino)pyridazin‐3‐yl)‐5‐fluoro‐3‐methylphenol ( 17 b ), which meets the preclinical profile of a successful imaging agent, and whose tritiated version demonstrated excellent specificity in a radioligand saturation binding assay, confirming its imaging potential. 18 F labeling led to [ 18 F]NP3‐627 , the proposed PET imaging agent.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Positron-Emission TomographyNLR Family, Pyrin Domain-Containing 3 ProteinPyridazinesInflammasomesRadiopharmaceuticalsCentral Nervous SystemFluorine RadioisotopesAnimalsHumansMiceMolecular StructureStructure-Activity Relationship

Stichwörter der Autor:innen

NLRP3Positron Emission Tomographyimaging agentinflammasomeradioligand binding assay

Substanzen

NLR Family, Pyrin Domain-Containing 3 ProteinPyridazinesFluorine RadioisotopesInflammasomesRadiopharmaceuticalsFluorine-18

Autor:innen und Institutionen

  • Novartis Biomedical Research, Global Discovery Chemistry, Novartis Campus, WSJ-88.10.110, 4056, Basel, Switzerland.
  • Novartis Biomedical Research, Immunology Research, Novartis Campus, WSJ-386, 4056, Basel, Switzerland.
  • ETH Zurich, Institute of Pharmaceutical Sciences, Vladimir-Prelog Weg 4, 8093, Zurich, Switzerland.

ORCID-Profile: Christian Fischer, Emmanuelle Briard, Christopher J Farady, Klemens Kaupmann, Guillaume Lapointe, Angela Mackay, Lisa Reichert, Linjing Mu, Yves P Auberson

Zitieren

APA

Whitehead, D. M., Fischer, C., Briard, E., Farady, C. J., Graveleau, N., Karrer, J., Kaupmann, K., Lapointe, G., Mackay, A., Reichert, L., Wright, M., Mu, L., & Auberson, Y. P. (2025). [ 18 F]NP3‐627, a Candidate PET Imaging Agent Targeting the NLRP3 Inflammasome in the Central Nervous System. ChemMedChem, 20(4). https://doi.org/10.1002/cmdc.202400816

Vancouver

Whitehead DM, Fischer C, Briard E, Farady CJ, Graveleau N, Karrer J, et al. [ 18 F]NP3‐627, a Candidate PET Imaging Agent Targeting the NLRP3 Inflammasome in the Central Nervous System. ChemMedChem. 2025;20(4). doi:10.1002/cmdc.202400816

BibTeX
@article{Whitehead2025,
  author = {Whitehead, David M and Fischer, Christian and Briard, Emmanuelle and Farady, Christopher J and Graveleau, Nadège and Karrer, Joel and Kaupmann, Klemens and Lapointe, Guillaume and Mackay, Angela and Reichert, Lisa and Wright, Michael and Mu, Linjing and Auberson, Yves P},
  title = {[ 18 F]NP3‐627, a Candidate PET Imaging Agent Targeting the NLRP3 Inflammasome in the Central Nervous System},
  journal = {ChemMedChem},
  year = {2025},
  volume = {20},
  number = {4},
  doi = {10.1002/cmdc.202400816}
}
Kostenlos starten →